Mostrar el registro sencillo

dc.contributor.authorMartínez Taboada, Víctor Manuel es_ES
dc.contributor.authorBlanco-Olavarri, Pedroes_ES
dc.contributor.authorDel Barrio-Longarela, Saraes_ES
dc.contributor.authorRiancho Zarrabeitia, Leyrees_ES
dc.contributor.authorMerino Fernández, Ana Isabel es_ES
dc.contributor.authorComins-Boo, Alejandraes_ES
dc.contributor.authorLópez Hoyos, Marcos es_ES
dc.contributor.authorHernández Hernández, José Luis es_ES
dc.contributor.otherUniversidad de Cantabriaes_ES
dc.date.accessioned2023-02-24T15:16:55Z
dc.date.available2023-02-24T15:16:55Z
dc.date.issued2022-11-15es_ES
dc.identifier.issn2227-9059es_ES
dc.identifier.urihttps://hdl.handle.net/10902/27891
dc.description.abstractThis study aims to compare the demographic characteristics, clinical features, serology, and fetal-maternal outcomes between women with obstetric antiphospholipid syndrome (APS) and those with non-criteria (NC)-APS and seronegative (SN)-APS. Two-hundred and sixty-three women with APS obstetric morbidity ever pregnant were included. Of those, 66 met the APS classification criteria, 140 were NC-APS, and 57 were SN-APS. Patients with other autoimmune diseases were excluded. Adverse pregnancy outcomes (APO) included early pregnancy loss, fetal death, preeclampsia, abruptio placentae, and preterm birth. The mean age of the study group was 33.6 ± 5.3 years, and patients were followed up for 129.5 ± 81.9 months. In the NC-APS group, 31 (22.1%) did not fulfill clinical and serological criteria (Subgroup A), 49 (35%) did meet clinical but not serologic criteria (Subgroup B), and 60 (42.9%) fulfilled the serologic criteria but not the clinical ones (Subgroup C). The cardiovascular risk burden was higher in the APS group, due to a higher proportion of smoking. Patients with criteria APS received more intensive treatment than patients in the other study groups. The addition of standard of care (SoC) treatment significantly improved live birth and decreased APO in all groups. Significant clinical differences were observed between the study groups. However, when treated with SoC, fetal-maternal outcomes were similar, with a significant improvement in live births and a decrease in APO. Risk stratification in patients with obstetric morbidity associated with APS can help individualize their treatment.es_ES
dc.format.extent15 p.es_ES
dc.language.isoenges_ES
dc.publisherMDPI AGes_ES
dc.rightsAttribution 4.0 International*
dc.rights© 2022 by the authors. Licensee MDPI, Basel, Switzerlandes_ES
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.sourceBiomedicines 2022, 10, 2938es_ES
dc.subject.otherAntiphospholipid antibodieses_ES
dc.subject.otherAntiphospholipid syndromees_ES
dc.subject.otherFetal losses_ES
dc.subject.otherNon-criteriaes_ES
dc.subject.otherObstetric morbidityes_ES
dc.subject.otherPregnancyes_ES
dc.titleNon-criteria obstetric antiphospholipid syndrome: how different is from Sidney criteria? A single-center studyes_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.rights.accessRightsopenAccesses_ES
dc.identifier.DOI10.3390/biomedicines10112938es_ES
dc.type.versionpublishedVersiones_ES


Ficheros en el ítem

Thumbnail

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo

Attribution 4.0 InternationalExcepto si se señala otra cosa, la licencia del ítem se describe como Attribution 4.0 International